Features

Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. Which companies are expanding and who is leading the charge?

The industry has weighed in on the US government’s potential plan to impose tariffs specific to the pharmaceutical industry. Where does the initiative stand, and what is the industry saying?

Capital flow in the biotech sector has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?

New modalities, ADCs and bispecific antibodies, accounted for $18 billion in cancer medicine spending in 2024 and are fast-growing on a pipeline basis. What else stands out in the oncology drug market?

In times of supply-chain uncertainty, a new DCAT Research & Benchmarking report addresses a key question in the pharma customer–supplier relationship: What does it take to become a “Customer of…

Antibody drug conjugates (ADCs) have been a strong niche in the global oncology drug market. What are the leading commercial ADCs and key pipeline contenders, and will ADCs continue to bode well for CDMOs/CMOs? A look at what lies ahead.

Emerging Pharma companies are an important partner to larger companies in drug development and as customers to CDMOs/CMOs. What has been the impact thus far on evolving US trade policy, including tariffs, and changes in healthcare policy and funding? DCAT Value Chain Insights takes an inside look.

President Donald Trump issued an Executive Order this week to lay out a plan to implement most-favored-nation drug pricing as a way to reduce differentials in drug pricing between the US and foreign countries as means to lower the cost of Rx drugs in the US. What’s the impact of pharma manufactuers?

President Donald Trump signed an Executive Order this week to facilitate drug manufacturing in the US, including calling for measures to streamline FDA and EPA review of domestic pharma manufacturing and enhance review of foreign drug-manufacturing facilities. What’s next?

Riding the strength of GLP-1 agonists and renewed interest in peptide-based development, several CDMOs are proceeding with large-scale investments in peptide development and manufacturing as other companies are joining the peptide space.